These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 34817311)

  • 21. Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.
    Weir MR; McCullough PA; Buse JB; Anderson J
    Am J Nephrol; 2020; 51(4):276-288. PubMed ID: 32172239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink.
    Cook S; Schmedt N; Broughton J; Kalra PA; Tomlinson LA; Quint JK
    BMJ Open; 2023 Mar; 13(3):e065927. PubMed ID: 36882249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.
    Folkerts K; Kelly AMB; Petruski-Ivleva N; Fried L; Blankenburg M; Gay A; Velentgas P; Kovesdy CP
    Nephron; 2021; 145(4):342-352. PubMed ID: 33789294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AWAREness of Diagnosis and Treatment of Chronic Kidney Disease in Adults With Type 2 Diabetes (AWARE-CKD in T2D).
    Chu L; Bhogal SK; Lin P; Steele A; Fuller M; Ciaccia A; Abitbol A
    Can J Diabetes; 2022 Jul; 46(5):464-472. PubMed ID: 35739044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey.
    Nouraei H; Leiter LA; Tan MK; Langer A; Teoh H; Cheng AYY; Wald R; Connelly KA; Goodman SG; Yan AT
    Can J Diabetes; 2021 Dec; 45(8):743-749. PubMed ID: 33839025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the management of chronic kidney disease.
    Chen TK; Hoenig MP; Nitsch D; Grams ME
    BMJ; 2023 Dec; 383():e074216. PubMed ID: 38052474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.
    Ali S; Dave N; Virani SS; Navaneethan SD
    Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes.
    O'Keefe JH; Nassif ME; Magwire ML; O'Keefe EL; Lavie CJ
    Prog Cardiovasc Dis; 2019; 62(4):364-369. PubMed ID: 31408637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Geographical variation in kidney function testing and associations with health care costs among patients with chronic kidney disease and type 2 diabetes.
    Betts KA; Song J; Elliott J; Warnock N; Farej R; Wu A; Singh R
    Am J Manag Care; 2022 Aug; 28(6 Suppl):S112-S119. PubMed ID: 35997775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA.
    Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M
    Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiorenal disease management in type 2 diabetes: An expert consensus.
    Mohan V; Singh AK; Zargar AH; Almeida A; Bhalla AK; Mohan JC; Dalal J; Sahay M; Mohanan PP; Maitra S; Ghosh S; Jeloka T; Kaul U; Sakhuja V; Das MK
    Diabetes Metab Syndr; 2022 Dec; 16(12):102661. PubMed ID: 36375366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.
    Zanchi A; Jehle AW; Lamine F; Vogt B; Czerlau C; Bilz S; Seeger H; de Seigneux S
    Swiss Med Wkly; 2023 Jan; 153():40004. PubMed ID: 36652726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials.
    Garcia Sanchez JJ; Thompson J; Scott DA; Evans R; Rao N; Sörstadius E; James G; Nolan S; Wittbrodt ET; Abdul Sultan A; Stefansson BV; Jackson D; Abrams KR
    Adv Ther; 2022 Jan; 39(1):193-220. PubMed ID: 34881414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants.
    Olufade T; Lamerato L; Sánchez JJG; Jiang L; Huang J; Nolan S; Rangaswami J
    Adv Ther; 2021 Feb; 38(2):1352-1363. PubMed ID: 33474707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
    Giorgino F; Vora J; Fenici P; Solini A
    Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
    Green JB; Mottl AK; Bakris G; Heerspink HJL; Mann JFE; McGill JB; Nangaku M; Rossing P; Scott C; Gay A; Agarwal R
    Nephrol Dial Transplant; 2023 Mar; 38(4):894-903. PubMed ID: 35700142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Making treatment guideline recommendations in chronic kidney disease and type 2 diabetes more accessible to primary care providers in the United States.
    Wright EE; Nicholas SB
    Postgrad Med; 2024 May; 136(4):347-357. PubMed ID: 38712604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.